Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.

M. Apicella, C. Migliore, T. Capeloa, S. Menegon, M. Cargnelutti, M. Degiuli, A. Sapino, A. Sottile, I. Sarotto, L. Casorzo, P. Cassoni, M. De Simone, P. M. Comoglio, S. Marsoni, S. Corso, S. Giordano

Research output: Contribution to journalArticle

Abstract

Amplification of the MET oncogene occurs in 2-4% of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have been disappointing, showing few and short lasting responses. The aim of the work was to exploit a MET-amplified patient-derived xenograft model to optimize anti-MET therapeutic strategies in gastroesophageal cancer. We found that despite the high MET amplification level (26 gene copies), in the absence of qualitative or quantitative alterations of EGFR, MET inhibitors induced only tumor growth inhibition, whereas dual MET/EGFR inhibition led to complete tumor regression. Importantly, the combo treatment completely prevented the onset of resistance, which quite rapidly appeared in tumors treated with MET monotherapy. We found that this secondary resistance was due to EGFR activation and could be overcome by dual MET/EGFR inhibition. Similar results were also obtained in a MET-addicted, established gastric cancer cell line. In vitro experiments performed on tumor-derived primary cells confirmed that MET inhibitors were not able to abrogate the activation of downstream transducers and that only the combined MET/EGFR treatment completely shut off the signaling. Previously reported cases, as well as those described here, showed only partial and transient sensitivity to anti-MET therapy. The finding that combined anti-MET/EGFR therapy-even in the absence of EGFR genetic alterations-induced complete and durable response, represents a proof of concept and guarantees further investigations, opening a new perspective of treatment for these patients.
Original languageEnglish
Pages (from-to)1200-1210
Number of pages11
JournalOncogene
Volume36
Publication statusPublished - Mar 1 2017

Fingerprint

Neoplasms
Therapeutics
Transducers
Oncogenes
Heterografts
Stomach Neoplasms
Clinical Trials
Cell Line
Growth
Genes
In Vitro Techniques

Keywords

  • Aged, 80 and over, Animals, Antineoplastic Combined Chemotherapy Protocols/*pharmacology, Apoptosis/drug effects, Biomarkers, Tumor/genetics, Cell Proliferation/drug effects, Cetuximab/administration & dosage, Drug Resistance, Neoplasm/*genetics, Esophageal Neoplasms/*drug therapy/genetics/pathology, Esophagogastric Junction/drug effects, *Gene Amplification, Humans, Male, Mice, Mice, Inbred NOD, Mice, SCID, Phosphorylation, Proto-Oncogene Proteins c-met/*antagonists & inhibitors, Quinazolines/administration & dosage, Receptor, Epidermal Growth Factor/*antagonists & inhibitors, Signal Transduction, Stomach Neoplasms/*drug therapy/genetics/pathology, Tumor Cells, Cultured, Xenograft Model Antitumor Assays

Cite this

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. / Apicella, M.; Migliore, C.; Capeloa, T.; Menegon, S.; Cargnelutti, M.; Degiuli, M.; Sapino, A.; Sottile, A.; Sarotto, I.; Casorzo, L.; Cassoni, P.; De Simone, M.; Comoglio, P. M.; Marsoni, S.; Corso, S.; Giordano, S.

In: Oncogene, Vol. 36, 01.03.2017, p. 1200-1210.

Research output: Contribution to journalArticle

@article{6d620f74575b4350a7a0ed7049896f30,
title = "Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.",
abstract = "Amplification of the MET oncogene occurs in 2-4{\%} of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have been disappointing, showing few and short lasting responses. The aim of the work was to exploit a MET-amplified patient-derived xenograft model to optimize anti-MET therapeutic strategies in gastroesophageal cancer. We found that despite the high MET amplification level (26 gene copies), in the absence of qualitative or quantitative alterations of EGFR, MET inhibitors induced only tumor growth inhibition, whereas dual MET/EGFR inhibition led to complete tumor regression. Importantly, the combo treatment completely prevented the onset of resistance, which quite rapidly appeared in tumors treated with MET monotherapy. We found that this secondary resistance was due to EGFR activation and could be overcome by dual MET/EGFR inhibition. Similar results were also obtained in a MET-addicted, established gastric cancer cell line. In vitro experiments performed on tumor-derived primary cells confirmed that MET inhibitors were not able to abrogate the activation of downstream transducers and that only the combined MET/EGFR treatment completely shut off the signaling. Previously reported cases, as well as those described here, showed only partial and transient sensitivity to anti-MET therapy. The finding that combined anti-MET/EGFR therapy-even in the absence of EGFR genetic alterations-induced complete and durable response, represents a proof of concept and guarantees further investigations, opening a new perspective of treatment for these patients.",
keywords = "Aged, 80 and over, Animals, Antineoplastic Combined Chemotherapy Protocols/*pharmacology, Apoptosis/drug effects, Biomarkers, Tumor/genetics, Cell Proliferation/drug effects, Cetuximab/administration & dosage, Drug Resistance, Neoplasm/*genetics, Esophageal Neoplasms/*drug therapy/genetics/pathology, Esophagogastric Junction/drug effects, *Gene Amplification, Humans, Male, Mice, Mice, Inbred NOD, Mice, SCID, Phosphorylation, Proto-Oncogene Proteins c-met/*antagonists & inhibitors, Quinazolines/administration & dosage, Receptor, Epidermal Growth Factor/*antagonists & inhibitors, Signal Transduction, Stomach Neoplasms/*drug therapy/genetics/pathology, Tumor Cells, Cultured, Xenograft Model Antitumor Assays",
author = "M. Apicella and C. Migliore and T. Capeloa and S. Menegon and M. Cargnelutti and M. Degiuli and A. Sapino and A. Sottile and I. Sarotto and L. Casorzo and P. Cassoni and {De Simone}, M. and Comoglio, {P. M.} and S. Marsoni and S. Corso and S. Giordano",
year = "2017",
month = "3",
day = "1",
language = "English",
volume = "36",
pages = "1200--1210",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.

AU - Apicella, M.

AU - Migliore, C.

AU - Capeloa, T.

AU - Menegon, S.

AU - Cargnelutti, M.

AU - Degiuli, M.

AU - Sapino, A.

AU - Sottile, A.

AU - Sarotto, I.

AU - Casorzo, L.

AU - Cassoni, P.

AU - De Simone, M.

AU - Comoglio, P. M.

AU - Marsoni, S.

AU - Corso, S.

AU - Giordano, S.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Amplification of the MET oncogene occurs in 2-4% of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have been disappointing, showing few and short lasting responses. The aim of the work was to exploit a MET-amplified patient-derived xenograft model to optimize anti-MET therapeutic strategies in gastroesophageal cancer. We found that despite the high MET amplification level (26 gene copies), in the absence of qualitative or quantitative alterations of EGFR, MET inhibitors induced only tumor growth inhibition, whereas dual MET/EGFR inhibition led to complete tumor regression. Importantly, the combo treatment completely prevented the onset of resistance, which quite rapidly appeared in tumors treated with MET monotherapy. We found that this secondary resistance was due to EGFR activation and could be overcome by dual MET/EGFR inhibition. Similar results were also obtained in a MET-addicted, established gastric cancer cell line. In vitro experiments performed on tumor-derived primary cells confirmed that MET inhibitors were not able to abrogate the activation of downstream transducers and that only the combined MET/EGFR treatment completely shut off the signaling. Previously reported cases, as well as those described here, showed only partial and transient sensitivity to anti-MET therapy. The finding that combined anti-MET/EGFR therapy-even in the absence of EGFR genetic alterations-induced complete and durable response, represents a proof of concept and guarantees further investigations, opening a new perspective of treatment for these patients.

AB - Amplification of the MET oncogene occurs in 2-4% of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have been disappointing, showing few and short lasting responses. The aim of the work was to exploit a MET-amplified patient-derived xenograft model to optimize anti-MET therapeutic strategies in gastroesophageal cancer. We found that despite the high MET amplification level (26 gene copies), in the absence of qualitative or quantitative alterations of EGFR, MET inhibitors induced only tumor growth inhibition, whereas dual MET/EGFR inhibition led to complete tumor regression. Importantly, the combo treatment completely prevented the onset of resistance, which quite rapidly appeared in tumors treated with MET monotherapy. We found that this secondary resistance was due to EGFR activation and could be overcome by dual MET/EGFR inhibition. Similar results were also obtained in a MET-addicted, established gastric cancer cell line. In vitro experiments performed on tumor-derived primary cells confirmed that MET inhibitors were not able to abrogate the activation of downstream transducers and that only the combined MET/EGFR treatment completely shut off the signaling. Previously reported cases, as well as those described here, showed only partial and transient sensitivity to anti-MET therapy. The finding that combined anti-MET/EGFR therapy-even in the absence of EGFR genetic alterations-induced complete and durable response, represents a proof of concept and guarantees further investigations, opening a new perspective of treatment for these patients.

KW - Aged, 80 and over, Animals, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Apoptosis/drug effects, Biomarkers, Tumor/genetics, Cell Proliferation/drug effects, Cetuximab/administration & dosage, Drug Resistance, Neoplasm/genetics, Esophageal

M3 - Article

VL - 36

SP - 1200

EP - 1210

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -